Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts

SpringerPlus

Volumn 4, Issue 1, 2015, Pages

  Cook, Matthew T ^a,b   Liang, Yayun ^a,b   Besch Williford, Cynthia ^c   Goyette, Sandy ^a,b   Mafuvadze, Benford ^a,b   Hyder, Salman M ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c IDEXX BioResearch ^*  (United States)

Author keywords

Breast cancer; Luteolin; Medroxyprogesterone acetate; Therapeutic; Tumor growth

Indexed keywords

EID: 84940187777     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/s40064-015-1242-x     Document Type: Article

References (31)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100:3983–3988
2. Axlund SD, Sartorius CA (2012) Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol 357:71–79
3. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C, Fotsis T (2004) Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 64:7936–7946
4. Brisken C (2013) Progesterone signaling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 13:385–396
5. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane DS, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTieman A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA 289:3243–3253. doi:10.1001/jama.289.24.3243
6. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587. doi:10.1056/NEJMoa0807684
7. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK (2013) Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene 32:2555–2564. doi:10.1038/onc.2012.275
8. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–30
9. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567
10. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364
11. Horwitz KB (1992) The molecular biology of RU486. is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:146–163
12. Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93:3295–3298
13. Horwitz KB, Wei LL, Sedlacek SM, d’Arville CN (2013) Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res 41:249–316
14. Hyder SM, Murthy L, Stancel GM (1998) Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58:392–395
15. Hyder SM, Huang J-C, Nawaz Z, Boettger-Tong H, Mäkelä S, Chiappetta C, Stancel GM (2000) Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 108(Suppl 5):785–790
16. Knutson TP, Lange CA (2014) Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther 142:114–125
17. Liang Y, Hyder SM (2005) Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology 146:3632–3641
18. Liang Y, Brekken RA, Hyder SM (2006) Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 13:905–919
19. Liang Y, Besch-Williford C, Brekken RA, Hyder SM (2007) Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 67:9929–9936
20. Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, Hyder SM (2010) Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause (New York, NY) 17:1040
21. Liu S, Dontu G, Wicha MS (2005) Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 7:86
22. Mafuvadze B, Benakanakere I, Hyder SM (2010) Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells. Menopause 17:1055–1063
23. Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM (2012) Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm Cancer 3:160–171
24. MWS Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427
25. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332
26. Seelinger G, Merfort I, Wölfle U, Schempp CM (2008) Anti-carcinogenic effects of the flavonoid luteolin. Molecules 13:2628–2651
27. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
28. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112
29. Tsai SA, Stefanick ML, Stafford RS (2011) Trends in menopausal hormone therapy use of US office-based physicians, 2000–2009. Menopause (New York, NY) 18:385
30. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333. doi:10.1001/jama.288.3.321
31. Wu J, Richer J, Horwitz KB, Hyder SM (2004) Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells preferential regulation by progesterone receptor B. Cancer Res 64:2238–2244